Immunicum AB (publ) announces the result of the subscription to the LTI 2021/2024 incentive program

Closes Release

September 29, 2021

Immunicum AB (released) Announces the result of the subscription in LTI 2021/2024 Incentive Program

Immunicum AB (publ) today announced the results the subscription of employee shares options and limit shares in the incentive program LTI 2021/2024 resolved through Annual General Meeting of 4 May 2021. In total, 1,286,092 employee stock options and 660.000 restricted stock units have been subscribed, representing a dilution of 0.97 percent I fall employee stock options and limit share units are exercised.

The Shareholders’ Meeting of May 4, 2021 decided to set up a performance incentive program (“LTI 2021/2024“). The incentive plan includes stock options for employees (the “2021/2024 Employee Stock Option Program) and restricted stock units (the “2021/2024 Restricted Share Unit Program“).

The 2021/2024 employee stock option program
The 2021/2024 employee stock option program is aimed at senior executives and key employees of the group and includes a maximum of 1,678,453 employee stock options. In total, 1,286,092 employee stock options were subscribed and granted. Each employee stock purchase option gives its holder the right to subscribe to one (1) new share of the Company during the exercise period at a subscription price corresponding to SEK 7.35, which corresponds to 140 percent of the volume weighted average price paid during the period starting May 5, 2021 through May 19, 2021 inclusive of the stated prices paid for the Company’s shares. The exercise period begins on September 1, 2024 until October 31, 2024 inclusive.

The 2021/2024 restricted share unit program
The 2021/2024 restricted share unit program is aimed at other group employees and includes a maximum of 834,300 restricted share units. In total, 660,000 restricted stock units were subscribed and granted. Each restricted share unit confers on its holder the right to subscribe to one (1) new share of the Company during the exercise period at a subscription price corresponding to the value of the share of the share. The current value of the quota is SEK 0.05 per share. The exercise period begins on September 1, 2024 until October 31, 2024 inclusive.

The information in this press release is information that Immunicum AB (publ) is obligated to disclose in accordance with the Nasdaq Stockholm regulations for issuers. The information has been made public through the agency of the contact persons indicated below To 8h00 THISSTonne 29 September, 2021.

FOR MORE INFORMATION PLEASE CONTACT:

Erik Manting

Chief Executive Officer

Telephone: +31 713 322 627

Email: [email protected]

RELATIONS WITH INVESTORS

Kristina Windrup Olander

Spikinc AB

Telephone: +46 72 545 34 74

Email: [email protected]

MEDIA RELATIONS

Sophia Hergenhan & Jacob Verghese

Trophic Communication

Telephone: +49 89 2388 7731

Email: [email protected]

IN REGARDS TO IMMUNICUM AB (PUBL)
Immunicum is a biopharmaceutical company specializing in hard-to-treat, established tumors and prevention of cancer recurrence, two key challenges in oncology. We are leveraging our unrivaled expertise in allogeneic dendritic cell biology to develop an advanced clinical pipeline of novel, ready-to-use cell therapies for solid and hematogenous tumors. Based in Sweden and the Netherlands, Immunicum is listed on Nasdaq Stockholm.
www.immunicum.com

Attachment

About Georgia Duvall

Check Also

AXA launches strategic program to build a digital business platform

Global insurer AXA has announced the launch of a strategic program to build a digital …

Leave a Reply

Your email address will not be published.